We are live on !
Find out more
ACA
Acorn Capital Advisors Portfolio holdings
AUM
$366M
Turnover
17.39%
1-Year Est. Return
474.6%
This Fund
S&P 500
This Quarter Est. Return
+48.27%
1 Year Est. Return
+474.6%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$366M
AUM Growth
+$14.6M
(+4.2%)
Cap. Flow
-$74.2M
Cap. Flow % of AUM
Cap. Flow %
-20.25%
Top 10 Holdings %
Top 10 Hldgs %
90.19%
Holding
23
New
1
Increased
5
Reduced
3
Closed
3
Avg Time Held
1.2
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$10.7M |
| 2 |
enGene Therapeutics
ENGN
|
+$5.18M |
| 3 |
Jade Biosciences
JBIO
|
+$4.17M |
| 4 |
Aura Biosciences
AURA
|
+$2.38M |
| 5 |
CG Oncology
CGON
|
+$65.3K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$92.1M |
| 2 |
Cardiff Oncology
CRDF
|
+$2.85M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$967K |
| 4 |
Q32 Bio
QTTB
|
+$826K |
| 5 |
Bicara Therapeutics
BCAX
|
+$22 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$5.73B
| $80.4M | 21.94% |
1,131,500
+999
| +0.1% | +$65.3K |
2024 Q4
6 quarters
|
|
2
UroGen Pharma
URGN
$1.6B
| $61.6M | 16.8% |
1,673,420
| – | – |
2024 Q4
6 quarters
|
|
3
Trevi Therapeutics
TRVI
$1.93B
| $40M | 10.92% |
2,144,844
| – | – |
2024 Q4
6 quarters
|
|
4
Candel Therapeutics
CADL
$637M
| $36M | 9.83% |
3,497,948
| – | – |
2024 Q4
6 quarters
|
|
5
Puma Biotechnology
PBYI
$539M
| $33.5M | 9.14% |
4,131,299
| – | – |
2024 Q4
6 quarters
|
|
|
6
Jade Biosciences
JBIO
$894M
| $21.9M | 5.98% |
986,760
+200,000
| +25% | +$4.17M |
2026 Q1
1 quarter
|
|
|
7
Bicara Therapeutics
BCAX
$604M
| $19.1M | 5.21% |
643,381
-1
| -0% | -$22 |
2024 Q4
6 quarters
|
|
|
8
Karyopharm Therapeutics
KPTI
$15M
| $14.8M | 4.05% |
1,518,113
+1,230,287
| +427% | +$10.7M |
2026 Q1
1 quarter
|
|
9
OnKure Therapeutics
OKUR
$106M
| $12.9M | 3.53% |
2,839,674
| – | – |
2024 Q4
6 quarters
|
|
|
HELP
10
Helus Pharma Inc. Common Stock
HELP
$775M
| $10.2M | 2.78% |
1,540,266
| – | – |
2024 Q4
6 quarters
|
|
11
Protara Therapeutics
TARA
$147M
| $6.69M | 1.83% |
1,752,115
| – | – |
2024 Q4
6 quarters
|
|
|
12
Aura Biosciences
AURA
$637M
| $6.6M | 1.8% |
929,077
+333,333
| +56% | +$2.38M |
2025 Q1
5 quarters
|
|
13
LeonaBio Inc
LONA
$46.5M
| $5.83M | 1.59% |
634,539
| – | – |
2025 Q4
2 quarters
|
|
14
Verastem
VSTM
$1.18B
| $5.61M | 1.53% |
1,469,153
| – | – |
2024 Q4
6 quarters
|
|
15
Whitehawk Therapeutics
WHWK
$185M
| $5.22M | 1.42% |
1,139,363
| – | – |
2024 Q4
6 quarters
|
|
|
16
Q32 Bio
QTTB
$265M
| $2.75M | 0.75% |
216,171
-98,881
| -31% | -$826K |
2024 Q4
6 quarters
|
|
|
17
enGene Therapeutics
ENGN
$103M
| $2.2M | 0.6% |
+1,271,257
| New | +$5.18M |
2026 Q2
0 quarters
|
|
18
Jasper Therapeutics
JSPR
$17.3M
| $604K | 0.16% |
1,438,159
+26,667
| +2% | +$20K |
2025 Q3
3 quarters
|
|
19
DELISTED
BIOATLA INC
BCAB
| $448K | 0.12% |
108,126
-1
| -0% | -$4 |
2024 Q4
6 quarters
|
|
|
YARW
20
Yarrow Bioscience
YARW
$168M
| $926 | ﹤0.01% |
29
| – | – |
2024 Q4
6 quarters
|
|
|
21
Cardiff Oncology
CRDF
$69.2M
| – | – |
-1,762,084
| Closed | -$2.85M | – |
|
|
22
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-1,746,264
| Closed | -$92.1M | – |
|
|
23
X4 Pharmaceuticals
XFOR
$332M
| – | – |
-234,039
| Closed | -$967K | – |
|
Similar funds
SA
VST
Acorn Capital Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Acorn Capital Advisors held 23 positions worth $366M, up 4.2% from $352M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Acorn Capital Advisors withdrew a net $74.2M in Q2 2026, closing 3 positions and reducing 3 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $92.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Acorn Capital Advisors opened a new position in enGene Therapeutics worth $2.2M.
- Acorn Capital Advisors's largest Q2 2026 buy was enGene Therapeutics: 1,271,257 shares worth $2.2M.
- Acorn Capital Advisors added most to Karyopharm Therapeutics in Q2 2026, an estimated $10.7M increase.
- Acorn Capital Advisors's biggest Q2 2026 reduction was Q32 Bio, cutting an estimated $826K.
- Acorn Capital Advisors fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $92.1M.
- Acorn Capital Advisors's ten largest holdings make up 90% of its $366M portfolio in Q2 2026.
- Acorn Capital Advisors opened 1 new position and closed 3 in Q2 2026.
- Acorn Capital Advisors's portfolio value rose 4.2% quarter-over-quarter to $366M.
Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.